Express Healthcare reports that researchers from Queen’s University Belfast and the University of Cambridge have partnered with Almac Diagnostic Services to test for the first time a personalized approach that could enable clinicians to decide the most appropriate chemotherapy for early stage esophageal cancer.

A personalized medicine approach of tailoring treatment to the individual could lead to more patients having their tumors successfully removed and thereby improving the prognosis for quality of life.  The trial was funded by Cancer Research, UK. Follow the link to learn more about this story.

Lead Research/Investigator

Professor Rebecca Fitzgerald, University of Cambridge

Professor Richard Kennedy, Queen’s University Belfast & Global VP of Biomarker Development at Almac Diagnostic Services


Pin It on Pinterest